Format

Send to

Choose Destination
Semin Oncol. 2019 Dec;46(6):397-402. doi: 10.1053/j.seminoncol.2019.10.006. Epub 2019 Nov 11.

Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.

Author information

1
Center for Precision Medicine, Department of Medicine, University of Missouri School of Medicine, Columbia, MO.
2
The University of Texas, MD Anderson Cancer Center, Houston, TX.
3
Cardio-Oncology Program, Vanderbilt School of Medicine, Nashville, TN.
4
Department of Hematology, Jagiellonian University, Krakòw, Poland.
5
Department of Medicine, Campus Bio-Medico University, Rome, Italy. Electronic address: g.minotti@unicampus.it.

Abstract

The opening session of Second International Colloquium on Cardio-Oncology addressed two areas of vital interest. The first reviewed new thoughts related to established agents. While anthracycline cardiotoxicity has been studied and reviewed extensively, ongoing research attempting to understand why it appears the mechanism(s) of toxicity differs from that of oncologic efficacy continue to evoke comment and intriguing speculation. Better understanding of the role of β-topoisomerase II in toxicity has advanced our understanding of the cascade of events that lead to heart failure. Additionally, the cardioprotective role of dexrazoxane fits well with our new understanding of how β-topoisomerase II works. Beyond the anthracyclines, new insight is providing us insight to better understand the impact on cardiac function seen with other agents including those targeting HER2 and several tyrosine-kinase inhibitors. Unlike the anthracyclines, these agents affect cardiac function in ways that are less direct, and therefore have different characteristics and should be thought of in alternate ways. This new knowledge regarding established agents furthers our understanding of the spectrum of cardiotoxicity and cardiac dysfunction in the cancer patient. The session also addressed cardiovascular toxicities of newer and established agents beyond myocardial dysfunction including effects on the vasculature. These agents cause changes that may be temporary or permanent, and that range from subclinical to life-threatening. The session ended with a discussion of the cardiac effects of immune checkpoint inhibitors. These agents can cause rare and sometimes fatal cardiac inflammation, for which long-term follow up may be required.

KEYWORDS:

Angiogenesis inhibitors; Anthracyclines; Cardiovascular toxicity; Immune checkpoint inhibitors; Trastuzumab

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center